Patents
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
02/2010
02/23/2010US7666868 N-sulphonylpyrroles and their use as histone deacetylase inhibitors
02/23/2010US7666863 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
02/23/2010CA2462289C Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
02/23/2010CA2345146C Cyanophenyl derivative
02/18/2010WO2010019930A1 Urea derivatives as inhibitors of map kinases
02/18/2010WO2010019772A2 Oxadiazole-2-oxides as antischistosomal agents
02/18/2010WO2010019606A1 Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
02/18/2010WO2010019101A1 A crystalline form of 4- (5-{ (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } - 4 -methyl- 4h- 1, 2,4- triazol-3-yl) pyridine
02/18/2010WO2010019100A1 A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine
02/18/2010WO2010018686A1 Nitrogenated heterocyclic derivative, and agricultural or horticultural bactericidal agent
02/18/2010WO2010018328A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018198A1 Polymerizable benzoxazine compositions
02/18/2010US20100041886 Isoxazolo-pyrazine derivatives
02/18/2010US20100041721 Selective androgen receptor modulators
02/18/2010US20100041708 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation
02/18/2010US20100041706 Compounds 501
02/18/2010US20100041656 Novel amide derivatives and medicinal use thereof
02/18/2010US20100041655 Triazole derivative
02/18/2010US20100041654 Pyrimidine Derivatives And Their Use As CB2 Modulators
02/18/2010US20100041653 Composition and methods for the design and development of metallo-enzyme inhibitors
02/18/2010US20100041649 viricides used for for treating a human papillomavirus (HPV) viral infections, for inhibiting HPV DNA replication or for preventing prenatal transmission of HPV from mother to baby by administering to the mother prior to giving birth
02/18/2010US20100041647 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses
02/18/2010US20100041646 Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants
02/18/2010US20100041645 Rho kinase inhibitors
02/18/2010US20100041642 Urea inhibitors of map kinases
02/18/2010US20100041638 Chemical Compounds 293
02/18/2010US20100041637 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1
02/18/2010US20100041635 Oxindole compounds
02/18/2010US20100041628 Novel indole derivative having ikappab kinase beta inhibitory activity
02/18/2010US20100041555 3-Phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same
02/18/2010US20100040753 Flavor molecules
02/18/2010CA2733966A1 Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
02/18/2010CA2733922A1 A crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine
02/18/2010CA2733920A1 A new crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine
02/18/2010CA2733397A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010CA2733190A1 Oxadiazole-2-oxides as antischistosomal agents
02/17/2010EP2154138A1 Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof
02/17/2010EP2154130A1 Pyridone compound
02/17/2010EP2153832A2 Heterocyclic aspartyl protease inhibitors
02/17/2010EP2152701A1 Phenyl amino pyrimidine compounds and uses thereof
02/17/2010EP2152700A1 Csf-1r inhibitors, compositions, and methods of use
02/17/2010EP2152690A1 Pyridyl piperidine orexin receptor antagonists
02/17/2010EP2152674A1 Benzimidazolone chymase inhibitors
02/17/2010EP2152664A1 Dipeptide analogs as coagulation factor inhibitors
02/17/2010EP2152370A1 Aryl ether pyridazinone derivatives
02/17/2010EP2152082A1 Tetracyclic inhibitors of fatty acid amide hydrolase
02/17/2010EP2152079A1 Heterocyclic compounds and uses thereof
02/17/2010EP1902026B1 Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
02/17/2010CN101652361A 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors
02/17/2010CN101648947A 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
02/17/2010CN101648944A 病毒聚合酶抑制剂 Viral polymerase inhibitors
02/16/2010US7663001 Preparation of isoxazolin-3-ylacylbenzene
02/16/2010US7662977 Such as 2-cationic amino-4-oxo-chromene derivatives; water solubility, pharmacokinetics; reduced side effects; anticancer agents
02/16/2010US7662972 Insecticidal and acaricidal activity for many agricultural insect pests, spider mites; endo- or ecto-parasiticide for mammals or birds; veterinary medicine; environmentally friendly
02/16/2010US7662971 enzyme inhibitor for treating sleep disorders
02/16/2010US7662847 Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors
02/16/2010US7662839 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid
02/16/2010US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma
02/16/2010US7662818 e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis
02/16/2010US7662816 Cognition activators; neurodegenerative disorders; Alzheimer's disease
02/16/2010US7662814 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases
02/16/2010US7662813 Triazole compounds that modulate HSP90 activity
02/16/2010US7662811 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
02/16/2010US7662771 Drug delivery; controlled/sustained release
02/16/2010CA2571627C Substituted aryl-amine derivatives and methods of use
02/16/2010CA2478183C Substituted amides
02/16/2010CA2450922C Piperidines for use as orexin receptor antagonists
02/16/2010CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors
02/16/2010CA2385938C Cyclic amine compounds as ccr5 antagonists
02/11/2010WO2010017479A1 Triazole compounds that modulate hsp90 activity
02/11/2010WO2010017401A1 Bi-1h-benzimidazoles as hepatitis c virus inhibitors
02/11/2010WO2010017120A1 Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
02/11/2010WO2010017079A1 Oxazole derivatives useful as inhibitors of faah
02/11/2010WO2010016554A1 Cyclic amine compound
02/11/2010WO2010016549A1 Tricyclic compound
02/11/2010WO2010015985A1 Tricyclic alkylaminomethyloxazolidinone derivatives
02/11/2010WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
02/11/2010WO2010015613A1 Organic compounds
02/11/2010WO2010015090A1 Functionalized pyrrolidines and use thereof as iap inhibitors
02/11/2010WO2009154754A3 Synthesis of deuterated morpholine derivatives
02/11/2010WO2009139576A3 Pyridine derivatives substituted with novel benzoxazoles or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical compositions containing the same as active ingredients for prevention and treatment of abnormal cell growth disease
02/11/2010WO2008142550A9 Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
02/11/2010WO2008026216A3 Process for purification of aprepitant
02/11/2010US20100036118 Fused Ring Heterocycle Kinase Modulators
02/11/2010US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
02/11/2010US20100035929 Unnatural dispyrin analogues, preparation and uses thereof
02/11/2010US20100035880 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists
02/11/2010US20100035879 N-sulfonylcarboximidamide apoptosis promoters
02/11/2010US20100035874 Organic compounds
02/11/2010US20100034827 Novel hiv reverse transcriptase inhibitors
02/11/2010US20100034813 Substituted pyrazole and triazole compounds as ksp inhibitors
02/11/2010CA2732932A1 Organic compounds
02/11/2010CA2732526A1 Oxazole derivatives useful as inhibitors of faah
02/11/2010CA2731365A1 Tricyclic alkylaminomethyloxazolidinone derivatives
02/10/2010EP2151440A1 Heterocyclic compound and use thereof
02/10/2010EP2150551A1 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
02/10/2010EP2150543A2 Heterocyclic compounds with affinity to muscarinic receptors
02/10/2010EP2150539A1 Pyridazinone derivatives
02/10/2010EP2150115A1 Cyclopropyl pyrrolidine orexin receptor antagonists
02/10/2010EP1833805B1 New 3-phenylpropionic acid derivatives for the treatment of diabetes